MNG825
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.311
- KRAS_SIGNALING_DN+0.258
- HEDGEHOG_SIGNALING+0.226
- MYOGENESIS+0.225
- ANGIOGENESIS+0.222
- ESTROGEN_RESPONSE_EARLY+0.203
- SPERMATOGENESIS+0.198
- BILE_ACID_METABOLISM+0.189
- XENOBIOTIC_METABOLISM+0.182
- ESTROGEN_RESPONSE_LATE+0.171
Top 10 suppressed
- MYC_TARGETS_V2-0.522
- INTERFERON_ALPHA_RESPONSE-0.406
- OXIDATIVE_PHOSPHORYLATION-0.404
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.375
- PROTEIN_SECRETION-0.374
- MYC_TARGETS_V1-0.348
- UNFOLDED_PROTEIN_RESPONSE-0.331
- PI3K_AKT_MTOR_SIGNALING-0.287
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG326 | — | — | 0.856 |
| 2 | MNG1052 | — | — | 0.846 |
| 3 | MNG854 | — | — | 0.841 |
| 4 | SRR1352975 | GTEX | — | 0.828 |
| 5 | SRR1333352 | GTEX | — | 0.826 |
| 6 | MNG254 | — | — | 0.824 |
| 7 | SRR4296064 | — | cohortA1 | 0.816 |
| 8 | MNG251 | — | — | 0.815 |
| 9 | SRR8613724 | — | F | 0.810 |
| 10 | SRR1314958 | GTEX | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.311 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.258 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.226 | Inavolisib | — uncovered |
| MYOGENESIS | 0.225 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.222 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.203 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.198 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.182 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.171 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.145 | Inavolisib | — uncovered |
| PEROXISOME | 0.145 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.144 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.143 | Inavolisib | — uncovered |
| COAGULATION | 0.141 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.057 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.034 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.006 | Inavolisib | — uncovered |
| HYPOXIA | 0.002 | Idelalisib | — uncovered |